In a significant advancement for Alzheimer’s disease research, Anavex Life Sciences has reported promising results from its phase 2b/3 trial of blarcamesine
(ANAVEX®2-73). The investigational therapy demonstrated a noteworthy reduction
in amyloid-β biomarkers and a deceleration in brain atrophy among patients with
early Alzheimer’s disease. These findings mark a crucial step forward in the
fight against this debilitating condition.
The trial, which involved 508 participants across multiple research centers, aimed to evaluate
the efficacy of blarcamesine compared to a placebo.
Patients treated with the Anavex drug showed significant improvements in several clinical endpoints. Notably, there
was a marked increase in the plasma Aβ42/40 ratio, highlighting the drug’s
robust anti-amyloid effect. Additionally, MRI scans revealed a significant
reduction in whole brain volume loss, providing further evidence of the
therapy’s impact on neurodegeneration.
Dr. Marwan Noel Sabbagh, a leading neurology expert, emphasized the importance of these
findings. He noted that blarcamesine is one of the first therapies to show
efficacy on biomarkers of neurodegeneration while also slowing cognitive
decline. “The advantage of blarcamesine is that it is a small oral
molecule that provides clinical benefits on cognition and
neurodegeneration,” Sabbagh stated.
The study’s design was rigorous, employing a multicenter, randomized, double-blind,
placebo-controlled methodology. Participants were administered either
blarcamesine or a placebo daily for 48 weeks. The primary endpoints included
the Alzheimer’s Disease Assessment Scale-Cognitive and the Alzheimer’s Disease
Cooperative Study-Activities of Daily Living subscales. Results showed
statistically significant differences between the blarcamesine and placebo
groups, further validating the drug’s potential.
Christopher U Missling, PhD, CEO of Anavex Life Sciences, expressed his gratitude towards the study’s
participants and researchers. He highlighted the importance of these findings
in providing a potential new, convenient oral treatment option for Alzheimer’s disease.
As Anavex continues to advance its clinical development program, the hope is that blarcamesine will
offer a new avenue for treating Alzheimer’s, bringing much-needed relief to
millions affected by this devastating disease.
See related link for more information.
Learn more about Anavex Life Sciences on https://www.nasdaq.com/market-activity/stocks/avxl